Literature DB >> 2566050

Ten-year follow-up study of islet-cell antibodies and childhood diabetes mellitus.

G J Bruining1, J L Molenaar, D E Grobbee, A Hofman, G J Scheffer, H A Bruining, A M de Bruyn, H A Valkenburg.   

Abstract

To find out whether subclinical autoimmunity precedes onset of nonfamilial insulin-dependent diabetes mellitus (IDDM), 4806 schoolchildren aged 5-19 years from a township in Holland were followed-up for at least ten years after blood was sampled for measurement of islet-cell antibodies (ICA). ICA positivity conferred a relative risk of IDDM of 533 (95% CI 145-1955). In the 10 years of follow-up 4 of the 8 ICA-positive subjects became insulin dependent, whereas the probability of being free of IDDM was 99.9% for those who were ICA-negative at the start of the study. The findings suggest that, although chronic autoimmunity involving the pancreatic beta-cells may precede non-familial IDDM by many years, a positive ICA test on a single occasion predicts the development of IDDM in only 4 out of 8 subjects over a period of 10 years.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2566050     DOI: 10.1016/s0140-6736(89)92383-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Autoimmune polyglandular syndrome type 1.

Authors:  P Obermayer-Straub; C P Strassburg; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 2.  Diabetes mellitus.

Authors:  A B Johnson; R Taylor
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

3.  Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays.

Authors:  E Bonifacio; C Boitard; H Gleichmann; M A Shattock; J L Molenaar; G F Bottazzo
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

4.  Interleukin-1-beta, tumor necrosis factor-alpha, insulin secretion and oral glucose tolerance in non-diabetic siblings of children with IDDM.

Authors:  A el-Nawawy; T Soliman; O el-Azzouni; A A Abbassy; M N Massoud; S Marzouk; F Ibrahim; L Helal
Journal:  Indian J Pediatr       Date:  1998 May-Jun       Impact factor: 1.967

5.  Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes.

Authors:  M A Atkinson; M A Bowman; L Campbell; B L Darrow; D L Kaufman; N K Maclaren
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

6.  Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow-up study in type 1 (insulin-dependent) diabetic patients and in first-degree relatives.

Authors:  P Saï; A Elmansour; M Audrain; B Charbonnel; S Bardet
Journal:  Diabetologia       Date:  1993-08       Impact factor: 10.122

7.  Enhancing the understanding of pre-type 1 diabetes in the general population.

Authors:  Olli Simell; William E Winter; Desmond Schatz
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 17.152

8.  Prediction of type 1 diabetes in the general population.

Authors:  Mikael Knip; Sari Korhonen; Petri Kulmala; Riitta Veijola; Antti Reunanen; Olli T Raitakari; Jorma Viikari; Hans K Akerblom
Journal:  Diabetes Care       Date:  2010-06       Impact factor: 19.112

9.  Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry.

Authors:  C L Vandewalle; T Decraene; F C Schuit; I H De Leeuw; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

10.  Autoantibodies and genetic factors associated with the development of type 1 (insulin-dependent) diabetes mellitus in first degree relatives of diabetic patients.

Authors:  C Thivolet; B Beaufrère; L Geburher; P Chatelain; J Orgiazzi; R François
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.